RJA
ADMA icon

Raymond James & Associates’s ADMA Biologics ADMA Stock Holding History

Raymond James & Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.29M Sell
264,392
-13,835
-5% -$215K ﹤0.01% 1621
2024
Q2 		$3.11M Sell
278,227
-5,966
-2% -$50K ﹤0.01% 1896
2024
Q1 		$1.88M Buy
284,193
+34,897
+14% +$191K ﹤0.01% 2200
2023
Q4 		$1.13M Buy
249,296
+5,657
+2% +$20.9K ﹤0.01% 2444
2023
Q3 		$872K Buy
243,639
+10,018
+4% +$38.6K ﹤0.01% 2548
2023
Q2 		$862K Sell
233,621
-8,255
-3% -$30.6K ﹤0.01% 2570
2023
Q1 		$801K Buy
241,876
+5,023
+2% +$17.4K ﹤0.01% 2606
2022
Q4 		$919K Sell
236,853
-15,720
-6% -$48.5K ﹤0.01% 2478
2022
Q3 		$614K Sell
252,573
-16,083
-6% -$38.6K ﹤0.01% 2723
2022
Q2 		$532K Buy
268,656
+68,672
+34% +$135K ﹤0.01% 2877
2022
Q1 		$366K Buy
199,984
+38,715
+24% +$60.4K ﹤0.01% 3274
2021
Q4 		$227K Buy
161,269
+9,086
+6% +$11.9K ﹤0.01% 3621
2021
Q3 		$172K Buy
152,183
+29,029
+24% +$40.7K ﹤0.01% 3703
2021
Q2 		$197K Sell
123,154
-56,337
-31% -$99.1K ﹤0.01% 3692
2021
Q1 		$316K Buy
179,491
+43,202
+32% +$98.9K ﹤0.01% 3330
2020
Q4 		$266K Sell
136,289
-45,362
-25% -$95.4K ﹤0.01% 3196
2020
Q3 		$434K Sell
181,651
-76,813
-30% -$211K ﹤0.01% 2734
2020
Q2 		$757K Buy
258,464
+34,674
+15% +$99.6K ﹤0.01% 2333
2020
Q1 		$645K Buy
223,790
+103,545
+86% +$358K ﹤0.01% 2249
2019
Q4 		$481K Buy
120,245
+70,188
+140% +$306K ﹤0.01% 2762
2019
Q3 		$223K Buy
50,057
+806
+2% +$3.37K ﹤0.01% 3190
2019
Q2 		$191K Buy
49,251
+34,531
+235% +$152K ﹤0.01% 3281
2019
Q1 		$56K Sell
14,720
-12,151
-45% -$43K ﹤0.01% 3466
2018
Q4 		$64K Buy
26,871
+10,610
+65% +$52.5K ﹤0.01% 3360
2018
Q3 		$101K Sell
16,261
-5,059
-24% -$29.1K ﹤0.01% 3436
2018
Q2 		$96K Buy
+21,320
New +$106K ﹤0.01% 3405
2016
Q3 		– Sell
-10,891
Closed -$65K – 3215
2016
Q2 		$65K Buy
+10,891
New +$76.3K ﹤0.01% 2858

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Raymond James & Associates's ADMA Position: Q3 2024 in Review

Raymond James & Associates reduced its ADMA Biologics (ADMA) stake by 5% in Q3 2024, selling an estimated $215K and leaving 264,392 shares worth $5.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

Raymond James & Associates first reported a position in ADMA in Q2 2016 and has held it in 27 quarters since. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

  • Raymond James & Associates held 264,392 shares of ADMA Biologics worth $5.29M as of Q3 2024.
  • Raymond James & Associates sold 13,835 ADMA Biologics shares in Q3 2024, an estimated $215K.
  • ADMA Biologics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1621 holding.
  • Raymond James & Associates first reported a position in ADMA Biologics in Q2 2016 and has held it in 27 quarters since.
  • 306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.